Variceal rebleeding in cirrhotic patients Digestive System Other diseases of liver
Conditions
Interventions
Oral carvedilol tablets versus endoscopic band ligation
Carvedilol is 6.25 mg once daily for one week and if tolerated then 12.5 mg once daily until the study is completed (6 months after the last pa
Sponsors
Greater Glasgow & Clyde (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female aged =18 and <75yrs 2. Endoscopic diagnosis of oesophageal variceal bleeding 3. Cirrhosis (based on previous liver biopsy or clinical, biochemical and ultrasonographic findings)
Exclusion criteria
Exclusion criteria: 1. Age 75 years 2. Advanced malignancy or another condition associated with a life expectancy of < 6/12 months 3. Previous transjugular intrahepatic portosystemic shunt (TIPS) or porto-caval shunt surgery 4. Portal vein thrombosis 5. Obstructive airways disease 6. Severe peripheral vascular disease 7. Heart block 8. Severe heart failure 9. Pregnancy 10. Type I diabetes mellitus 11. Gastric variceal bleed 12. Treatment with beta blockers or alpha blockers within 4 weeks of index bleed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variceal rebleeding is monitored when it occurs during follow-up. Patients will be followed up until 6 months after the last patient is randomised. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mortality 2. Any upper gastointestinal bleeding is monitored when it occurs during follow-up | — |
Countries
United Kingdom
Outcome results
None listed